Castle Biosciences Aktie

Kaufen

Verkaufen

25,20 EUR +1,00 EUR +4,13 %

15:25:01

FSE

30,51 USD +0,52 USD +1,73 %

19:28:52

BTT

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Bei einem anderen Broker handeln

Marktkap.715,99 Mio. EUR

KGV42,74Div. Rendite0,00%

WKNA2PNH3

ISINUS14843C1053

SymbolCSTL

Castle Biosciences Aktien News

Sortieren:Datum Meistgelesen

20.06.24BusinesswireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14.06.24BusinesswireCastle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner

15.05.24BusinesswireCastle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

10.05.24BusinesswireCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution”

30.04.24BusinesswireCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma

11.04.24BusinesswireCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

10.04.24BusinesswireCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

10.04.24BusinesswireCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

04.04.24BusinesswirePresentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

02.04.24BusinesswireCastle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

25.03.24BusinesswireCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

12.03.24BusinesswireCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

08.03.24BusinesswireCastle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

07.03.24BusinesswireIn Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups

28.02.24BusinesswireCastle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

26.02.24BusinesswireStudy Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

07.02.24BusinesswireCastle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

14.01.24BusinesswireCastle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

09.01.24BusinesswireCastle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report

20.12.23BusinesswireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01.12.23BusinesswireStudy Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results

14.11.23BusinesswireCastle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

13.11.23BusinesswireCastle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year

08.11.23BusinesswireReal-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder

08.11.23BusinesswireCastle Biosciences to Present at Upcoming Investor Conferences

03.11.23BusinesswireCastle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

02.11.23BusinesswireEarly Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

24.10.23BusinesswireCastle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting

19.10.23BusinesswireCastle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2

18.10.23BusinesswireNew Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®

05.10.23BusinesswireDecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma

02.10.23BusinesswireCastle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus

25.09.23BusinesswireCastle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma

19.09.23BusinesswireCastle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry

14.09.23BusinesswireTissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

12.09.23BusinesswireCastle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory

08.09.23BusinesswireTissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus

06.09.23BusinesswireCastle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023

05.09.23BusinesswireCastle Biosciences to Participate in Upcoming Investor Conferences

07.08.23BusinesswireNew Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus

Castle Biosciences News

Castle Biosciences News: auf dieser Seite finden Sie alle Castle Biosciences News und Nachrichten zur Castle Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Castle Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Castle Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.